• Patients achieve HDV RNA decline, negativity in Lambda phase 2 study

    14 days ago - By Healio

    Results from a phase 2 study of Lambda for the treatment of hepatitis D showed a decline of HDV RNA in more than half of treated patients, according to a press release from Eiger BioPharmaceuticals.
    “Lambda interferon demonstrated better tolerability in HDV-infected patients who were previously treated with alpha-interferon,” study co-lead investigators Ohad Etzion, MD, from Soroka University Medical Center, and Saeed Hamid, MD, from Aga Khan University, said in the release. “Fewer episodes of cytopenia, flu-like symptoms, and psychiatric events in this study make Lambda
    Read more ...